X4 Pharmaceuticals (NASDAQ:XFOR) and Tenax Therapeutics (NASDAQ:TENX) Head-To-Head Analysis
by Sarita Garza · The Markets DailyX4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) and Tenax Therapeutics (NASDAQ:TENX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for X4 Pharmaceuticals and Tenax Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| X4 Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Tenax Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
X4 Pharmaceuticals presently has a consensus price target of $9.38, indicating a potential upside of 132.63%. Tenax Therapeutics has a consensus price target of $38.00, indicating a potential upside of 133.70%. Given Tenax Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than X4 Pharmaceuticals.
Risk & Volatility
X4 Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Profitability
This table compares X4 Pharmaceuticals and Tenax Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| X4 Pharmaceuticals | -1,106.30% | -94.90% | -48.09% |
| Tenax Therapeutics | N/A | -56.32% | -53.12% |
Earnings and Valuation
This table compares X4 Pharmaceuticals and Tenax Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| X4 Pharmaceuticals | $35.11 million | 10.83 | -$79.20 million | ($4.54) | -0.89 |
| Tenax Therapeutics | N/A | N/A | -$52.60 million | ($1.40) | -11.61 |
Tenax Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. Tenax Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Tenax Therapeutics beats X4 Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.